Stanford



Parth I Kumar

- Postdoctoral Medical Fellow, Nephrology
- Fellow in Medicine - Med/Nephrology

Bio

BIO

Dr. Parth Kumar is a Glomerular Disease Fellow and previous Chief Fellow in the Division of Nephrology at Stanford University, where his clinical and scholarly work centers on glomerular pathology. A committed clinician educator, he was named Intern Teacher of the Year during his internal medicine residency at UC Irvine and has developed curricula across internal medicine, radiology, and community cardiology programs for audiences ranging from resident physicians to underserved high school students. He founded the Infectious Disease Interest Group at UCSF and has mentored medical students through case reports and research projects presented at national conferences. Selected as a 2025 GlomCon Fellow—one of roughly 150 chosen from more than 800 applicants for the Virtual Glomerular Disease Fellowship—he continues to deepen his expertise in glomerular disease. Dr. Kumar earned his M.D. with Distinction from UCSF and a B.A. with Honors in Molecular and Cell Biology from UC Berkeley.

CLINICAL FOCUS

- Fellow
- Nephrology
- Glomerular Disease

PROFESSIONAL EDUCATION

- Fellowship, Stanford Health Care , Nephrology (2026)
- Residency, UC Irvine , Internal Medicine (2024)
- Doctor of Medicine, University of San Francisco (2021)
- BA, UC Berkeley (2016)

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Nephrology (Fellowship Program)

Publications

PUBLICATIONS

- **Calcified amorphous tumor in a patient receiving peritoneal dialysis with severe, treatment-refractory hyperphosphatemia.** *Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis*
  Kumar, P. I., Woo, J., Kambham, N., Chertow, G. M.
  2026: 8968608261479962

- **Acute elevated blood pressure in the inpatient setting.** *Heart (British Cardiac Society)*
  Etemadi, A., Kumar, P., Anderson, T. S., Chang, T. I.
  2025

- **Shiga Toxin-Directed Complement-Mediated Hemolytic Uremic Syndrome Treated with Eculizumab**
  Kumar, P., Siu, M., Tantisattamo, E., Ferrey, A. J.
  AMER SOC NEPHROLOGY.2023: 1060

- **Shiga Toxin-Directed Complement-Mediated Hemolytic Uremic Syndrome Treated with Eculizumab** *American Society of Nephrology*
  Kumar, P., Siu, M., Tantisattamo, E., Ferrey, A. J.
  2023: 1060

- **Evaluating Radioactive Analogs of Doxorubicin to Quantify ChemoFilter Binding and Whole-Body Positron Emission Tomography/ Magnetic Resonance Imaging for Drug Biodistribution.** *Journal of vascular and interventional radiology : JVIR*
  Kumar, P., Yee, C., Blecha, J. E., Hayes, T. R., Kilbride, B. F., Stillson, C., Losey, A. D., Mastria, E., Jordan, C. D., Huynh, T. L., Moore, T., Wilson, M. W., VanBrocklin, et al
  2022; 33 (6): 687-694

- **Morphological and Transcriptional Responses to CRISPRi Knockdown of Essential Genes in Escherichia coli.** *mBio*
  Silvis, M. R., Rajendram, M., Shi, H., Osadnik, H., Gray, A. N., Cesar, S., Peters, J. M., Hearne, C. C., Kumar, P., Todor, H., Huang, K. C., Gross, C. A.
  2021: e0256121

- **13th International HHT Scientific Conference : June 12-16, 2019, San Juan, Puerto Rico.** *Angiogenesis*
  2019; 22 (4): 585-631

- **Abstracts from the 2017 Society of General Internal Medicine Annual Meeting.** *Journal of general internal medicine*
  2017; 32 (Suppl 2): 83-808